Kite Pharmaceuticals, Inc.
Aug 8, 2017

Kite Reports Second Quarter 2017 Financial Results

SANTA MONICA, Calif.--(BUSINESS WIRE)-- Kite Pharma, Inc. (Nasdaq:KITE), a leading cell therapy company, today reported second quarter 2017 financial results and provided a corporate update for the period ended June 30, 2017.

"We've continued to make significant progress on key clinical and commercial milestones in the last six months alone," said Arie Belldegrun, M.D., FACS, Chairman, President, and Chief Executive Officer of Kite. "With the anticipated events on the horizon for the remainder of 2017, the potential for CAR-T to become one of the most powerful anti-cancer agents for certain patients may finally be realized."

Second Quarter 2017 Financial Results

Recent Highlights

Axicabtagene Ciloleucel (axi-cel) Regulatory and Clinical Development

KTE-C19 Development

CAR-T Pipeline

TCR Pipeline

Axi-cel Commercial Preparation

Intellectual Property

Second Half 2017 Milestones

Axi-cel

KTE-C19

KITE-585

About Kite

Kite is a biopharmaceutical company engaged in the development of innovative cancer immunotherapies with a goal of providing rapid, long-term durable response and eliminating the burden of chronic care. The company is focused on chimeric antigen receptor (CAR) and T cell receptor (TCR) engineered cell therapies designed to empower the immune system's ability to recognize and kill tumors. Kite is based in Santa Monica, CA. For more information on Kite, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release may, in some cases, use terms such as "predicts," "believes," "potential," "proposed," "continue," "estimates," "anticipates," "expects," "expected," "plans," "intends," "may," "could," "might," "will," "should" or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the ability and timing of obtaining regulatory approval based on the studies of axicabtagene ciloleucel, commercially launching axicabtagene ciloleucel, advancing additional product candidates, including KTE-C19, KITE-718 and KITE-585, and meeting the second half 2017 milestones, and Kite's ability to maintain intellectual property protection. Various factors may cause differences between Kite's expectations and actual results as discussed in greater detail in Kite's filings with the Securities and Exchange Commission, including without limitation in its Form 10-Q for the quarter ended June 30, 2017. Any forward-looking statements that are made in this press release speak only as of the date of this press release. Kite assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Conference Call and Webcast Details

Kite will host a live conference call and webcast today at 5:30 AM Pacific Time (8:30 AM Eastern Time) to discuss financial results and provide a business update. To access the live conference call by telephone, please dial 888-771-4371 (U.S.) or 847-585-4405 (International). The conference ID number for the live call is 45253546. The webcast will be made available on the Company's website at www.kitepharma.com under the Investors tab in the Events and Presentations section. Following the live audio webcast, a replay will be available on the Company's website for approximately 30 days.

   
KITE PHARMA, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
   

JUNE 30, 2017
(UNAUDITED)

DECEMBER 31,
2016

ASSETS
Current assets
Cash, cash equivalents, and marketable securities $ 781,111 $ 414,422
Prepaid expenses and other current assets   17,169   12,974
Total current assets 798,280 427,396
Property and equipment, net 49,722 44,409
Intangibles assets and goodwill, net 31,921 31,398
Other assets   27,190   21,101
Total assets $ 907,113 $ 524,304
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities
Accounts payable $ 15,803 $ 10,660
Deferred revenue 30,570 29,482
Accrued expenses and other current liabilities   42,191   15,000
Total current liabilities 88,564 55,142
Deferred revenue, less current portion 78,354 19,779
Contingent consideration 15,450 14,218
Other non-current liabilities   15,491   7,195
Total liabilities   197,859   96,334
Total stockholders' equity   709,254   427,970

Total liabilities and stockholders' equity

$ 907,113 $ 524,304
 
         
KITE PHARMA, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)
 
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
  2017     2016     2017     2016  
Revenue $ 10,052 $ 4,795 $ 19,888 $ 9,922
Operating expenses:
Research and development 70,870 47,356 136,777 81,771
General and administrative   41,101     23,713     76,466     40,395  
Total operating expenses   111,971     71,069     213,243     122,166  
Loss from operations (101,919 ) (66,274 ) (193,355 ) (112,244 )
Total other income (expense) (1,144 ) 920 (170 ) 1,766
Income tax (provision) benefit   (6,759 )   1,080     (6,698 )   2,289  
Net loss $ (109,822 ) $ (64,274 ) $ (200,223 ) $ (108,189 )
Net loss per share, basic and diluted $ (1.94 ) $ (1.31 ) $ (3.69 ) $ (2.21 )
Weighted-average shares outstanding, basic and diluted   56,663     49,157     54,264     48,877  
 

Note Regarding Use of Non-GAAP Financial Measures

Kite provides non-GAAP net loss and non-GAAP net loss per share that include adjustments to U.S. Generally Accepted Accounting Principles (GAAP) figures. These adjustments to GAAP net loss exclude non-cash stock-based compensation expense. Kite believes that these non-GAAP financial measures, when considered together with the GAAP figures, can enhance an overall understanding of Kite's financial performance. The non-GAAP financial measures are included with the intent of providing investors with a more complete understanding of Kite's operating results. In addition, these non-GAAP financial measures are among the indicators Kite's management uses for planning purposes and measuring Kite's performance. These non-GAAP financial measures should be considered in addition to, and not as a substitute for, or superior to, financial measures calculated in accordance with GAAP. The non-GAAP financial measures used by Kite may be calculated differently from, and therefore may not be comparable to, non-GAAP financial measures used by other companies. Please refer below for a reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures.

         
KITE PHARMA, INC.
Reconciliation of GAAP to Non-GAAP Net Loss
(In thousands, except per share amounts)
 
THREE MONTHS ENDED SIX MONTHS ENDED
JUNE 30, JUNE 30,
  2017     2016     2017     2016  
Net loss - GAAP $ (109,822 ) $ (64,274 ) $ (200,223 ) $ (108,189 )
Adjustments:
Non-cash stock-based compensation expense   25,163     19,758     49,241     34,622  
Net loss - Non-GAAP $ (84,659 ) $ (44,516 ) $ (150,982 ) $ (73,567 )
 
Net loss per share, basic and diluted - GAAP $ (1.94 ) $ (1.31 ) $ (3.69 ) $ (2.21 )
Adjustments:
Non-cash stock-based compensation expense per share   0.44     0.40     0.91     0.71  
Net loss per share, basic and diluted - Non-GAAP $ (1.50 ) $ (0.91 ) $ (2.78 ) $ (1.50 )
Weighted-average shares outstanding, basic and diluted   56,663     49,157     54,264     48,877  
 

KITE CONTACT:
Christine Cassiano
SVP, Corporate Communications & Investor Relations
ccassiano@kitepharma.com
or
Greg Mann
VP, Investor Relations
gmann@kitepharma.com

Source: Kite Pharma, Inc.

News Provided by Acquire Media